Literature DB >> 17558437

Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig.

A Gupta1, M Gillard, B Christophe, P Chatelain, R Massingham, M Hammarlund-Udenaes.   

Abstract

BACKGROUND AND
PURPOSE: The H(1) receptor occupancy (H1RO) in brain is an indicator of central side effects of antihistamines. Here, we determined the kinetics of central and peripheral H1RO by levocetirizine in relation to its brain and plasma concentration, and investigated the role of the blood-brain barrier in any delay in brain H1RO. EXPERIMENTAL APPROACH: Concentration-time profiles in plasma and brain were obtained after 0.1 and 1 mg kg(-1) oral doses of levocetirizine in guinea pigs. H1RO in brain was measured ex vivo using [3H]-mepyramine and, in the periphery, by measuring the degree of inhibition of histamine-induced contractions of isolated guinea pig ileum. KEY
RESULTS: The concentration-time profile of levocetirizine indicated lower levels (partition coefficient, K(p)=0.06-0.08), higher t(max) (2-4 h vs 1-1.5 h) and longer terminal half-life (4-5.6 h vs 2.1-2.8 h) in brain than plasma. The H1RO at 0.1 and 1 mg kg(-1) were 75% and 97%, respectively, at 1 hr in the periphery and, in the brain, were <20% and 28-67% respectively, at all time points studied. Brain H1RO vs plasma concentrations profile showed a delay, but not when compared to brain concentrations. CONCLUSIONS AND IMPLICATIONS: This study demonstrates an effective peripheral antihistamine effect of levocetirizine without central adverse effects at the dose close to human therapeutic dose. The slow increase in H1RO in the brain with time was caused by slow blood-brain barrier transport of levocetirizine. This demonstrates the importance of measuring time course of brain H1RO in relation to brain concentrations of drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17558437      PMCID: PMC2042936          DOI: 10.1038/sj.bjp.0707318

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine.

Authors:  I Tamai; Y Kido; J Yamashita; Y Sai; A Tsuji
Journal:  J Drug Target       Date:  2000       Impact factor: 5.121

2.  Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194).

Authors:  Michel Gillard; Christy Van Der Perren; Nicole Moguilevsky; Roy Massingham; Pierre Chatelain
Journal:  Mol Pharmacol       Date:  2002-02       Impact factor: 4.436

Review 3.  Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography.

Authors:  T Watanabe; K Yanai
Journal:  Tohoku J Exp Med       Date:  2001-12       Impact factor: 1.848

4.  Preclinical comparison of ebastine and other second generation H1-antihistamines.

Authors:  I Yakuo; M Yabuuchi; T Ito
Journal:  Pharmacol Toxicol       Date:  2001-10

5.  Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine.

Authors:  M Tagawa; M Kano; N Okamura; M Higuchi; M Matsuda; Y Mizuki; H Arai; R Iwata; T Fujii; S Komemushi; T Ido; M Itoh; H Sasaki; T Watanabe; K Yanai
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

6.  Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

Authors:  Kelly M Mahar Doan; Joan E Humphreys; Lindsey O Webster; Stephen A Wring; Larry J Shampine; Cosette J Serabjit-Singh; Kimberly K Adkison; Joseph W Polli
Journal:  J Pharmacol Exp Ther       Date:  2002-12       Impact factor: 4.030

Review 7.  The effects of antihistamines on cognition and performance.

Authors:  G G Kay
Journal:  J Allergy Clin Immunol       Date:  2000-06       Impact factor: 10.793

8.  The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare.

Authors:  I Hindmarch; S Johnson; R Meadows; T Kirkpatrick; Z Shamsi
Journal:  Curr Med Res Opin       Date:  2001       Impact factor: 2.580

9.  A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers.

Authors:  J L Devalia; C De Vos; F Hanotte; E Baltes
Journal:  Allergy       Date:  2001-01       Impact factor: 13.146

10.  Histamine H1 receptor antagonism by cetirizine in isolated guinea pig tissues: influence of receptor reserve and dissociation kinetics.

Authors:  Bernard Christophe; Brigitte Carlier; Michel Gillard; Pierre Chatelain; Mike Peck; Roy Massingham
Journal:  Eur J Pharmacol       Date:  2003-05-30       Impact factor: 4.432

View more
  7 in total

1.  Improved measurement of drug exposure in the brain using drug-specific correction for residual blood.

Authors:  Markus Fridén; Helena Ljungqvist; Brian Middleton; Ulf Bredberg; Margareta Hammarlund-Udenaes
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-16       Impact factor: 6.200

2.  Management of chronic spontaneous urticaria in the elderly.

Authors:  Maria Teresa Ventura; Nicoletta Cassano; Paolo Romita; Michelangelo Vestita; Caterina Foti; Gino Antonio Vena
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

3.  Histamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory.

Authors:  P van Ruitenbeek; A Vermeeren; W J Riedel
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

4.  Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain-a Game Changing Parameter for CNS Drug Discovery and Development.

Authors:  Irena Loryan; Andreas Reichel; Bo Feng; Christoffer Bundgaard; Christopher Shaffer; Cory Kalvass; Dallas Bednarczyk; Denise Morrison; Dominique Lesuisse; Edmund Hoppe; Georg C Terstappen; Holger Fischer; Li Di; Nicola Colclough; Scott Summerfield; Stephen T Buckley; Tristan S Maurer; Markus Fridén
Journal:  Pharm Res       Date:  2022-04-11       Impact factor: 4.580

5.  Synthesis and antihistaminic activity of 3H-benzo [4,5] thieno [2,3-d][1,2,3] triazin-4-ones.

Authors:  Gollapalle L Viswanatha; B Janaki Priyadarshini; Nandakumar Krishnadas; Saravanan Janardhanan; Srinath Rangappa; Shylaja Hanumanthappa
Journal:  Saudi Pharm J       Date:  2011-05-24       Impact factor: 4.330

6.  Development and characterization of pharmacokinetic parameters of fast-dissolving films containing levocetirizine.

Authors:  Dhagla R Choudhary; Vishnu A Patel; Usmangani K Chhalotiya; Harsha V Patel; Aliasgar J Kundawala
Journal:  Sci Pharm       Date:  2012-07-22

7.  Levocetirizine Pretreatment Mitigates Lipopolysaccharide-Induced Lung Inflammation in Rats.

Authors:  Alaa N A Fahmi; George S G Shehatou; Hatem A Salem
Journal:  Biomed Res Int       Date:  2018-08-13       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.